Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Starboard has accused Pfizer of “coercive conduct” after executives who initially backed the hedge fund retracted their ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer (NYSE: PFE) ...

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ...

Pfizer is set to present initial findings from its CULTIVATE study of Velsipity (etrasimod) in Crohn’s disease (CD) at UEG ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation ...

Rates of spontaneous preterm labor were 13.7% for the hematologic cancer-associated pregnancies versus 3.6% for those among ...

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

How can women and men balance a demanding work lifestyle with cancer diagnosis and treatment? Survivors discuss their ...